Source: Eur Respir J 2016; 47: 783-791
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Vries Maaike de, Bedke Nicole, Smithers Natalie P., Loxham Matthew, Howarth Peter H., Nawijn Martijn C., Davies Donna E.. Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations. Eur Respir J 2016; 47: 783-791

Member's Comments

No comment yet.

Related content which might interest you: Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Profiling the impact of two JAK inhibitors in a pre-clinical model of allergic asthma Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018 Year: 2019 Targeting PI3Kd attenuates influenza virus-induced inflammation in a murine model of asthma exacerbation Source: International Congress 2017 – Infection and exacerbation science Year: 2017 Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 LATE-BREAKING ABSTRACT: The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Role of IκB kinases (IKKs) α and β in severe asthma and COPD Source: Eur Respir J 2005; 26: Suppl. 49, 2s Year: 2005 Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 Roles of PI3k pan-inhibitors and PI3k-d inhibitors in allergic lung inflammation: systematic review and a meta-analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Selective activation and targeting of autophagy in severe asthma. Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations Source: Eur Respir J, 50 (4) 1602434; 10.1183/13993003.02434-2016 Year: 2017 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016